Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11845-011-0716-2.pdf
Reference17 articles.
1. Heaney LG, Brightling CE, Menzies-Gow A et al (2010) Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 65(9):787–794
2. Moore WC, Bleecker ER, Curran-Everett D et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 119(2):405–413
3. Lloyd A, Price D, Brown R (2007) The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 16(1):22–27
4. Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139(1):28–35
5. Firszt R, Kraft M (2010) Pharmacotherapy of severe asthma. Curr Opin Pharmacol 10(3):266–271
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Economic evaluation of biological treatments in patients with severe asthma: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-09
2. Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access;BMJ Open Respiratory Research;2022-09
3. Direct cost analysis for patients with severe asthma receiving omalizumab treatment;Journal of Health Sciences and Medicine;2021-09-05
4. Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma;The Korean Journal of Internal Medicine;2021-07-01
5. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma;Tuberk Toraks;2021-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3